These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 29677098)
1. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Yoo J; Hann HW; Coben R; Conn M; DiMarino AJ Diseases; 2018 Apr; 6(2):. PubMed ID: 29677098 [TBL] [Abstract][Full Text] [Related]
2. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. Shinn BJ; Martin A; Coben RM; Conn MI; Prieto J; Kroop H; DiMarino AJ; Hann HW World J Hepatol; 2019 Jan; 11(1):65-73. PubMed ID: 30705719 [TBL] [Abstract][Full Text] [Related]
3. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. Rapti I; Hadziyannis S World J Hepatol; 2015 May; 7(8):1064-73. PubMed ID: 26052395 [TBL] [Abstract][Full Text] [Related]
4. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. Baran B World J Hepatol; 2015 Jul; 7(13):1742-54. PubMed ID: 26167247 [TBL] [Abstract][Full Text] [Related]
5. Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma. Kim SR; Kim SK Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892033 [TBL] [Abstract][Full Text] [Related]
6. Review of Related Factors for Persistent Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma. Varghese N; Majeed A; Nyalakonda S; Boortalary T; Halegoua-DeMarzio D; Hann HW Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398168 [TBL] [Abstract][Full Text] [Related]
7. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799 [TBL] [Abstract][Full Text] [Related]
8. New horizon for radical cure of chronic hepatitis B virus infection. Tajiri K; Shimizu Y World J Hepatol; 2016 Jul; 8(21):863-73. PubMed ID: 27478536 [TBL] [Abstract][Full Text] [Related]
9. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844 [TBL] [Abstract][Full Text] [Related]
10. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704 [TBL] [Abstract][Full Text] [Related]
11. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474 [TBL] [Abstract][Full Text] [Related]
12. New paradigms in hepatitis B management: only diamonds are forever. Coffin CS; Lee SS Br Med Bull; 2015; 116():79-91. PubMed ID: 26377741 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908 [TBL] [Abstract][Full Text] [Related]
14. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B]. Lu FM; Wang J; Chen XM; Jiang JN; Zhang WH; Zhao JM; Ren H; Hou JL; Xia NS Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):105-110. PubMed ID: 28297795 [TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269 [TBL] [Abstract][Full Text] [Related]
16. [Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC]. Han C; Lai PP; Dou XG Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):827-830. PubMed ID: 31941235 [TBL] [Abstract][Full Text] [Related]
17. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma? Abu-Amara M; Feld JJ Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672 [TBL] [Abstract][Full Text] [Related]
18. Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma. Tsai HW; Lin YJ; Wu HC; Chang TT; Wu IC; Cheng PN; Yen CJ; Chan SH; Huang W; Su IJ Oncotarget; 2016 May; 7(19):27724-34. PubMed ID: 27027237 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis B: progress in understanding chronicity, the innate immune response, and cccDNA protection. Morikawa K; Shimazaki T; Takeda R; Izumi T; Umumura M; Sakamoto N Ann Transl Med; 2016 Sep; 4(18):337. PubMed ID: 27761441 [TBL] [Abstract][Full Text] [Related]